Development of novel microRNA-based therapeutics platform for colorectal cancer
Drug Resistance in Colorectal Cancer: Molecular Mechanisms and Therapeutic Strategies, Page: 83-92
2020
- 1Captures
Metric Options: CountsSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Captures1
- Readers1
Book Chapter Description
Despite extensive efforts for over 50 years, resistance to chemotherapeutic treatment remains a significant challenge for many different types of cancer including colon cancer. Chemoresistance presents such a major challenge due to the fact that there are several different factors that allow cancer cells to evade treatment such as the heterogeneous nature of colon cancer and the presence of highly resistant colon cancer stem cells. Cancer cells are very adaptable and can rely on epigenetic changes to rapidly respond to chemotherapeutic challenges. Through regulation of various different cellular pathways such as apoptosis and autophagy, cancer cells can overcome the challenge posed by therapeutics. Novel approaches are needed to address this challenge. One potential approach is using miRNA to sensitize colon cancer cells to therapeutic treatment. In this review, we highlight and discuss some of the recent advancements in strategies to combat chemoresistance associated with colon cancer stem cells by manipulating miRNAs.
Bibliographic Details
http://www.sciencedirect.com/science/article/pii/B9780128199374000054; http://dx.doi.org/10.1016/b978-0-12-819937-4.00005-4; http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85142027363&origin=inward; https://linkinghub.elsevier.com/retrieve/pii/B9780128199374000054; https://api.elsevier.com/content/article/PII:B9780128199374000054?httpAccept=text/xml; https://api.elsevier.com/content/article/PII:B9780128199374000054?httpAccept=text/plain; https://dul.usage.elsevier.com/doi/; https://dx.doi.org/10.1016/b978-0-12-819937-4.00005-4
Elsevier BV
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know